In prostate cancer, CD44 expression significantly correlates with IL-6, a STAT3-activating cytokine, and IL-6 or STAT3 inhibition both decrease CD44 and EMT-related protein levels in cancer cell lines (77, 78). Here, CD44 is linked to prostate carcinoma.